

# Kidney

**Protocol applies to all invasive carcinomas of renal tubular origin. It excludes Wilms tumors and tumors of urothelial origin.**

---

*Protocol revision date: January 2004  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition*

## **Procedures**

- **Incisional Biopsy (Needle or Wedge)**
- **Partial Nephrectomy**
- **Radical Nephrectomy**

## **Authors**

John R. Srigley, MD

Department of Laboratory Medicine, Credit Valley Hospital, Mississauga,  
Ontario, Canada

Mahul B. Amin, MD

Department of Pathology, Emory University Hospital, Atlanta, Georgia  
For the Members of the Cancer Committee, College of American Pathologists

**Previous contributor:** George Farrow, MD

**Surgical Pathology Cancer Case Summary (Checklist)**

*Protocol revision date: January 2004  
Applies to invasive carcinomas only  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition*

**\*KIDNEY: Biopsy**

**(Note: Use of checklist for biopsy specimens is optional)**

\*Patient name:

\*Surgical pathology number:

<b>Note: Check 1 response unless otherwise indicated.</b>
---

**\*MACROSCOPIC****\*Specimen Type**

\*  Incisional biopsy, needle

\*  Incisional biopsy, wedge

\*  Other (specify): \_\_\_\_\_

\*  Not specified

**\*Laterality**

\*  Right

\*  Left

\*  Not specified

**\*MICROSCOPIC****\*Histologic Type**

\*  Cannot be determined

\*  Conventional (clear cell) renal carcinoma

\*  Papillary renal carcinoma

\*  Chromophobe renal carcinoma

\*  Collecting duct carcinoma

\*  Sarcomatoid carcinoma arising in renal cell carcinoma  
(specify subtype): \_\_\_\_\_

\*  Renal cell carcinoma, unclassified

\*  Other (specify): \_\_\_\_\_

\*  Carcinoma, type cannot be determined

- 2                   \* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**\*Histologic Grade (Fuhrman Nuclear Grade)**

- \*  Not applicable
- \*  GX: Cannot be assessed
- \*  G1: Nuclei round, uniform, approximately 10  $\mu$ ; nucleoli inconspicuous or absent
- \*  G2: Nuclei slightly irregular, approximately 15  $\mu$ ; nucleoli evident
- \*  G3: Nuclei very irregular, approximately 20  $\mu$ ; nucleoli large and prominent
- \*  G4: Nuclei bizarre and multilobated, 20  $\mu$  or greater, nucleoli prominent, chromatin clumped

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified
- \*  Inflammation (type): \_\_\_\_\_
- \*  Glomerular disease (type): \_\_\_\_\_
- \*  Interstitial disease (type): \_\_\_\_\_
- \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Surgical Pathology Cancer Case Summary (Checklist)**

*Protocol revision date: January 2004  
Applies to invasive carcinomas only  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition*

**KIDNEY: Nephrectomy, Partial or Radical**

Patient name:

Surgical pathology number:

**Note: Check 1 response unless otherwise indicated.**

**MACROSCOPIC****Specimen Type** Partial nephrectomy Radical nephrectomy Other (specify): \_\_\_\_\_ Not specified**Laterality** Right Left Not specified**\*Tumor Site (check all that apply)**\*  Upper pole\*  Middle\*  Lower pole\*  Other (specify): \_\_\_\_\_\*  Not specified**Focality** Unifocal Multifocal**Tumor Size (largest tumor if multiple)**

Greatest dimension: \_\_\_ cm

\*Additional dimensions: \_\_\_ x \_\_\_ cm

 Cannot be determined (see Comment)

- 4 \* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Macroscopic Extent of Tumor (check all that apply)**

- Tumor limited to kidney  
 Tumor extension into perinephric tissues  
 Tumor extension beyond Gerota's fascia  
 Tumor extension into adrenal  
 Tumor extension into major veins

**MICROSCOPIC****Histologic Type**

- Clear cell (conventional) renal carcinoma  
 Papillary renal cell carcinoma  
 Chromophobe renal cell carcinoma  
 Collecting duct carcinoma  
 Sarcomatoid carcinoma arising in renal cell carcinoma  
     Specify: subtype \_\_\_\_\_ ; \_\_\_\_% of sarcomatoid element  
 Renal cell carcinoma, unclassified  
 Other (specify): \_\_\_\_\_  
 Carcinoma, type cannot be determined

**Histologic Grade (Fuhrman Nuclear Grade)**

- Not applicable  
 GX: Cannot be assessed  
 G1: Nuclei round, uniform, approximately 10  $\mu$ ; nucleoli inconspicuous or absent  
 G2: Nuclei slightly irregular, approximately 15  $\mu$ ; nucleoli evident  
 G3: Nuclei very irregular, approximately 20  $\mu$ ; nucleoli large and prominent  
 G4: Nuclei bizarre and multilobated, 20  $\mu$  or greater, nucleoli prominent, chromatin clumped  
 Other (specify): \_\_\_\_\_

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Pathologic Staging (pTNM)**Primary Tumor (pT)

- pTX: Primary tumor cannot be assessed
- pT0: No evidence of primary tumor
- pT1: Tumor 7 cm or less in greatest dimension, limited to the kidney
- pT1a: Tumor 4 cm or less in greatest dimension, limited to the kidney
- pT1b: Tumor more than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney
- pT2: Tumor more than 7 cm in greatest dimension, limited to the kidney
- pT3: Tumor extends into major veins or invades adrenal gland or perinephric tissues but not beyond Gerota's fascia
- pT3a: Tumor directly invades adrenal gland or perirenal and/or renal sinus fat but not beyond Gerota's fascia
- pT3b: Tumor grossly extends into the renal vein or its segmental (muscle-containing) branches, or vena cava below the diaphragm
- pT3c: Tumor grossly extends into vena cava above diaphragm or invades the wall of the vena cava
- pT4: Tumor invades beyond Gerota's fascia

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
- pN0: No regional lymph node metastasis
- pN1: Metastasis in a single regional lymph node
- pN2: Metastasis in more than 1 regional lymph node
- Specify: Number examined: \_\_\_\_
- Number involved: \_\_\_\_

Distant Metastasis (pM)

- pMX: Cannot be assessed
- pM1: Distant metastasis
- \*Specify site(s), if known: \_\_\_\_\_

**Margins (check all that apply)**

- Cannot be assessed
- Margins uninvolved by invasive carcinoma
- Margin(s) involved by invasive carcinoma
- Renal capsular margin (partial nephrectomy only)
- Perinephric fat margin (partial nephrectomy only)
- Renal vein margin
- Gerota's fascial margin
- Ureteral margin
- Renal parenchymal margin (partial nephrectomy only)
- Other (specify): \_\_\_\_\_

**Adrenal Gland**

- Not present
- Uninvolved by tumor
- Direct invasion (T3a)
- Metastasis (M1)

**\*Venous (Large Vessel) Invasion (V)**

(excluding renal vein and inferior vena cava)

- \*  Absent
- \*  Present
- \*  Indeterminate

**\*Lymphatic (Small Vessel) Invasion (L)**

- \*  Absent
- \*  Present
- \*  Indeterminate

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified
- \*  Inflammation (type): \_\_\_\_\_
- \*  Glomerular disease (type): \_\_\_\_\_
- \*  Interstitial disease (type): \_\_\_\_\_
- \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

## Background Documentation

---

*Protocol revision date: January 2004*

### **I. Incisional Biopsy (Needle or Wedge)**

#### **A. Clinical Information**

1. Patient identification
  - a. Name
  - b. Identification number
  - c. Age (birth date)
  - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
  - a. Relevant history (eg, previous diagnoses and treatment, family history of renal tumors)
  - b. Relevant findings (eg, imaging studies)
  - c. Clinical diagnosis
  - d. Procedure (eg, needle biopsy)
  - e. Anatomic site(s) of specimen (eg, left kidney)

#### **B. Macroscopic Examination**

1. Specimen
  - a. Unfixed/fixed (specify fixative)
  - b. Number of pieces
  - c. Dimensions
  - d. Descriptive features
  - e. Orientation, if designated by surgeon
  - f. Results of intraoperative consultation
2. Tissue submitted for microscopic evaluation, as appropriate
  - a. Entire specimen
  - b. Selected sample
  - c. Frozen section tissue fragment(s) (unless saved for special studies)
3. Special studies (specify) (eg, histochemistry, immunohistochemistry, morphometry, cytogenetic analysis)

#### **C. Microscopic Evaluation**

1. Tumor
  - a. Histologic type (if possible) (Note **A**)
  - b. Histologic grade (Note **B**)
  - c. Venous/lymphatic vessel invasion, if possible to determine
  - d. Extracapsular extension, if possible to determine
2. Additional pathologic findings, if present
3. Result/status of special studies (specify)
4. Comments
  - a. Correlation with intraoperative consultation, as appropriate
  - b. Correlation with other specimens, as appropriate
  - c. Correlation with clinical information, as appropriate



**II. Partial Nephrectomy****A. Clinical Information**

1. Patient identification
  - a. Name
  - b. Identification number
  - c. Age (birth date)
  - d. Sex
2. Responsible physician(s)
3. Date of procedure
4. Other clinical information
  - a. Relevant history (eg, previous diagnoses and treatment, family history of renal tumors)
  - b. Relevant findings (eg, imaging studies)
  - c. Clinical diagnosis
  - d. Procedure (Note **C**)
  - e. Operative findings
  - f. Anatomic site(s) of specimen (eg, left partial kidney, upper pole)

**B. Macroscopic Examination**

1. Specimen
  - a. Organs/tissues included
  - b. Unfixed/fixed (specify fixative)
  - c. Type of specimen (Note **C**)
  - d. Kidney size (3 dimensions)
  - e. Weight
  - f. Orientation, if indicated by surgeon
  - g. Weight of adrenal gland, if present
  - h. Presence or absence of the following:
    - (1) renal capsule
    - (2) perirenal fat
  - i. Other organs/tissue(s) (weigh or measure, as appropriate)
  - j. Results of intraoperative consultation
2. Tumor(s)
  - a. Number
  - b. Location
  - c. Size(s) (Note **D**)
  - d. Descriptive characteristics (eg, solid/cystic, color, consistency, necrosis)
  - e. Extent of invasion (Note **D**)
  - f. Venous/lymphatic vessel invasion
3. Margins
  - a. Renal capsule
  - b. Renal vessels
  - c. Ureter
  - d. Cut surface of kidney, if heminephrectomy
4. Regional lymph nodes (Notes **D** and **E**)
  - a. Number
  - b. Location, if possible (Note **E**)
5. Tissues submitted for microscopic evaluation
  - a. Tumor (1 section for each centimeter of tumor diameter and/or different gross appearances)

- b. Non-neoplastic kidney (1 section minimum)
  - c. Sections to document tumor extent
    - (1) calyces, renal pelvis
    - (2) perirenal tissue, including hilus
    - (3) major blood vessels
  - d. All lymph nodes
  - e. Margins (all)
  - f. Adrenal gland (1 section minimum)
  - g. Frozen section tissue fragment(s) (unless saved for special studies)
  - h. Other tissue(s) (as appropriate)
6. Special studies (specify) (eg, histochemistry, immunohistochemistry, morphometry, DNA analysis [specify type], cytogenetic analysis)

### C. Microscopic Evaluation

- 1. Tumor
  - a. Histologic type (Note **A**)
  - b. Histologic grade (Note **B**)
  - c. Extent of invasion (Note **D**)
  - d. Venous/lymphatic vessel invasion (Note **D**)
- 2. Margins
  - a. Renal capsule
  - b. Renal vessels
  - c. Ureter
  - d. Cut surface of kidney, if heminephrectomy
- 3. Regional lymph nodes
  - a. Number
  - b. Number with metastasis<sup>#</sup> (Note **D**) (specify location, if possible)  
*# Measure largest involved node*
- 4. Metastasis to other organ(s) or structure(s) (specify site)
- 5. Additional pathologic findings, if present
- 6. Other tissue(s)/organ(s) (eg, adrenal gland)
- 7. Results/status of special studies (specify)
- 8. Comments
  - a. Correlation with intraoperative consultation, as appropriate
  - b. Correlation with other specimens, as appropriate
  - c. Correlation with clinical information, as appropriate

## III. Radical Nephrectomy

### A. Clinical Information

- 1. Patient identification
  - a. Name
  - b. Identification number
  - c. Age (birth date)
  - d. Sex
- 2. Responsible physician(s)
- 3. Date of procedure
- 4. Other clinical information
  - a. Relevant history (eg, previous diagnoses and treatment, family history of renal tumors)
  - b. Relevant findings (eg, imaging studies)

- c. Clinical diagnosis
- d. Procedure (eg, radical nephrectomy, with adrenalectomy, vena cava thrombectomy and lymphadenectomy) (Note **F**)
- e. Operative findings
- f. Anatomic site(s) of specimen (eg, left kidney)

**B. Macroscopic Examination**

1. Specimen
  - a. Organ(s)/tissue(s) included (Note **F**)
  - b. Unfixed/fixed (specify fixative)
  - c. Description of perirenal fat/Gerota's fascia
  - d. Weight of adrenal gland, if present
  - e. Kidney size (3 dimensions)
  - f. Weight
  - g. Length of ureter
  - h. Other submitted tissues (weigh or measure, as appropriate) (eg, venous tumor thrombus, specimens from other organs)
  - i. Results of intraoperative consultation
2. Tumor(s)
  - a. Number
  - b. Location
  - c. Size(s) (Note **D**)
  - d. Descriptive characteristics (eg, solid/cystic, color, consistency, necrosis)
  - e. Extent of invasion (Note **D**)
  - f. Hilar invasion
  - g. Renal vein invasion
3. Margins
  - a. Gerota's fascia
  - b. Renal vessels
  - c. Ureter
4. Regional lymph nodes (Notes **D** and **E**)
  - a. Number
  - b. Location, if possible
5. Separately submitted tissues (specify)
6. Tissue submitted for microscopic evaluation
  - a. Tumor (1 section for each centimeter of tumor diameter and/or different gross appearances)
  - b. Uninvolved kidney (1 section minimum)
  - c. Sections to document tumor extent
    - (1) calyces, renal pelvis
    - (2) ureter
    - (3) perirenal tissues, including hilus and Gerota's fascia
    - (4) renal vessels, including separately submitted tumor thrombus
  - d. All lymph nodes
  - e. Margins, as appropriate
  - f. Adrenal gland (1 section minimum)
  - g. Frozen section tissue fragment(s) (unless saved for special studies)
  - h. Other tissue(s), as appropriate
7. Special studies (specify)

**C. Microscopic Evaluation**

1. Tumor
  - a. Histologic type (Note **A**)
  - b. Histologic grade (Note **B**)
  - c. Extent of invasion (Note **D**)
  - d. Venous/lymphatic vessel invasion
2. Margins
  - a. Gerota's fascia
  - b. Renal vessels
  - c. Ureter
  - d. Other(s), as appropriate
3. Regional lymph nodes
  - a. Number (Note **D**)
  - b. Number with metastasis<sup>#</sup> (specify location, if possible) (Note **D**)  
<sup>#</sup> *Measure largest involved node*
4. Metastasis to other organs(s) or structure(s) (specify site)
5. Additional pathologic findings, if present
6. Other tissue(s)/organs
7. Results/status of special studies (specify)
8. Comments
  - a. Correlation with intraoperative consultation, as appropriate
  - b. Correlation with other specimens, as appropriate
  - c. Correlation with clinical information, as appropriate

**Explanatory Notes****A. Histologic Type**

The histopathologic classification most recently published by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) is recommended and shown below.<sup>1-3</sup> However, the protocol does not preclude the use of other published classifications<sup>4-11</sup> which appear in the Armed Forces Institute of Pathology (AFIP) *Atlas of Tumor Pathology*, 3rd series, Fascicle 11, "Tumors of the Kidney, Bladder and Related Urinary Structures," as shown below.<sup>4</sup>

**AJCC/UICC Histologic Classification of Renal Carcinoma**

Conventional (clear cell) renal carcinoma  
 Papillary renal carcinoma  
 Chromophobe renal carcinoma  
 Collecting duct carcinoma  
 Renal cell carcinoma, unclassified

**AFIP Histologic Classification of Renal Cell Carcinoma**

Clear cell (hypernephroid) renal cell carcinoma  
 Granular renal cell carcinoma<sup>#</sup>  
 Papillary renal cell carcinoma  
 Chromophobe renal cell carcinoma  
 Collecting duct-type renal cell carcinoma  
 Sarcomatoid renal cell carcinoma<sup>#,##</sup>  
 Mixed-type renal cell carcinoma

Renal cell carcinoma, undifferentiated

# These histologic types of renal cell carcinoma are not included in the AJCC/UICC classification shown above because it is argued that they may not represent unique forms of differentiation. Abundant granular cytoplasm may occur in any of the following tumor types: oncocytoma, chromophobe renal cell carcinoma, papillary renal cell carcinoma, collecting duct carcinoma, and epithelioid angiomyolipoma.

## Sarcomatoid morphology may be manifested by any renal cell carcinoma (conventional, papillary, chromophobe, collecting duct or unclassified subtypes), as well as urothelial carcinoma of the renal pelvis, and may represent a progression in tumor grade. Recent studies have shown that percentage of sarcomatoid component in a renal cell carcinoma may be prognostically important.<sup>12</sup>

### B. Histologic Grade

The following grading scheme for renal cell carcinoma developed by Fuhrman et al is recommended and shown below.<sup>13</sup> However, the protocol does not preclude the use of other grading schemes.<sup>14-18</sup> The system of grading should be specified in the pathologist's report.

Grade X	Cannot be assessed
Grade 1	Nuclei round, uniform, approximately 10 µm in diameter; nucleoli inconspicuous or absent
Grade 2	Nuclei slightly irregular, approximately 15 µm in diameter; nucleoli evident
Grade 3	Nuclei very irregular, approximately 20 µm in diameter; nucleoli large and prominent
Grade 4	Nuclei bizarre and multilobated, 20 µm or greater in diameter, nucleoli prominent, chromatin clumped.

### C. Operative Procedures

A partial nephrectomy may vary from a simple enucleation of the tumor to a partial nephrectomy including variable portions of the calyceal or renal pelvic collecting system. The perirenal fat immediately overlying the resected portion of kidney but not to the level of Gerota's fascia is usually included.

### D. TNM and Stage Groupings

The TNM staging system of the AJCC and UICC for renal cell carcinoma is recommended and shown below.<sup>19,20</sup>

By AJCC/UICC convention, the designation "T" refers to a primary tumor that has not been previously treated. The symbol "p" refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

### Primary Tumor (T)

TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
T1	Tumor 7 cm or less in greatest dimension, limited to the kidney
T1a	Tumor 4 cm or less in greatest dimension, limited to the kidney
T1b	Tumor more than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney
T2	Tumor more than 7 cm in greatest dimension, limited to the kidney
T3	Tumor extends into major veins or invades adrenal gland or perinephric tissues but not beyond Gerota's fascia
T3a	Tumor directly invades adrenal gland or perirenal and/or renal sinus fat but not beyond Gerota's fascia
T3b	Tumor grossly extends into the renal vein or its segmental (muscle-containing) branches, or vena cava below the diaphragm
T3c	Tumor grossly extends into vena cava above diaphragm or invades the wall of the vena cava
T4	Tumor invades beyond Gerota's fascia

Note: Direct invasion of the adrenal gland, which is categorized as local extension, must be differentiated from metastatic tumor in the adrenal, which is categorized M1 (see below for Distant Metastasis).

### Regional Lymph Nodes (N)<sup>#</sup> (see Note E)

NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node
N2	Metastasis in more than 1 regional lymph node

<sup>#</sup> Laterality does not affect the N classification.

### Distant Metastasis (M)

MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

### Stage Groupings

Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1	N1	M0
	T2	N1	M0
	T3	N0	M0

	T3	N1	M0
	T3a	N0	M0
	T3a	N1	M0
	T3b	N0	M0
	T3b	N1	M0
	T3c	N0	M0
	T3c	N1	M0
Stage IV	T4	N0	M0
	T4	N1	M0
	Any T	N2	M0
	Any T	Any N	M1

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

**Additional Descriptors****Residual Tumor (R)**

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

RX	Presence of residual tumor cannot be assessed
R0	No residual tumor
R1	Microscopic residual tumor
R2	Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**Vessel Invasion**

By AJCC/UICC convention, vessel invasion (lymphatic or venous) does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category. In all other cases, lymphatic and venous invasion by tumor are coded separately as follows.

Lymphatic Vessel Invasion (L)

LX	Lymphatic vessel invasion cannot be assessed
L0	No lymphatic vessel invasion
L1	Lymphatic vessel invasion

Venous Invasion (V)

VX	Venous invasion cannot be assessed
V0	No venous invasion
V1	Microscopic venous invasion
V2	Macroscopic venous invasion

**E. Lymph Nodes**

Regional lymphadenectomy is not generally performed even with a radical nephrectomy. A few lymph nodes may be found in a nephrectomy specimen in the renal hilus around the major renal vessels. Other regional lymph nodes (eg, paracaval, para-aortic, and retroperitoneal) may be submitted separately.

**F. Radical Nephrectomy**

A standard radical nephrectomy specimen consists of the entire kidney, including the calyces, pelvis and a variable length of ureter. The adrenal gland is usually removed en bloc with the kidney. The entire perirenal fatty tissue is removed to the level of Gerota's fascia, a membranous structure that is similar to the consistency of the renal capsule, which encases the kidney and perirenal fat. Variable lengths of the major renal vessels at the hilus are submitted. Some lymph nodes may be present in the renal hilus.

**References**

1. Störkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1 Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer*. 1997;80:987-989.
2. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. *Am J Surg Pathol*. 2002;26:281-291.
3. Amtrup F, Hausen JB, Thybo E. Prognosis in renal cell carcinoma evaluated from histological criteria. *Scand J Urol Nephrol*. 1974;8:198-202.
4. Murphy WM, Beckwith JB, Farrow GM. Tumors of the adult kidney. In: *Tumors of the Kidney, Bladder and Related Structures. Atlas of Tumor Pathology*. 3rd series. Fascicle 11. Washington, DC: Armed Forces Institute of Pathology; 1994:98-124.
5. Angervall L, Carlström E, Wahlqvist L, Ahren C. Effects of clinical and morphologic variables on spread of renal cell carcinoma in an operative series. *Scand J Urol Nephrol*. 1969;3:134-140.



6. Bennington JL. Tumors of the kidney. In: Javadpour N, Barsky SH, eds. *Surgical Pathology of Urologic Diseases*. Baltimore, Md: Williams and Wilkins; 1987:120-122.
7. Fleming S. The impact of genetics on the classification of renal carcinoma. *Histopathology*. 1993;22:89-92.
8. Kovacs G. Molecular differential pathology of renal cell tumours. *Histopathology*. 1993;22:1-8.
9. Mathisen W, Muri O, Myhre E. Pathology and prognosis in renal tumors. *Acta Chir Scand*. 1965;130:303-313.
10. Petkovic SD. An anatomical classification of renal tumors in the adult as a basis for prognosis. *J Urol*. 1959;81:618-623.
11. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). *Pathol Res Pract*. 1989;181:125-143.
12. de Perelta-Venturina M, Moch H, Amin M, et al. Sarcomatoid dedifferentiation in renal cell carcinoma: a study of 101 cases. *Am J Surg Pathol*. 2001;25:275-284.
13. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol*. 1982;6:655-663.
14. Arner O, Blanck C, van Schreeb T. Renal adenocarcinoma – morphology, grading of malignancy, prognosis: a study of 197 cases. *Acta Chir Scand*. 1965;346(suppl):1-51.
15. Hermanek P, Sigel A, Chlepas S. Histological grading of renal cell carcinoma. *Eur Urol*. 1976;2:189-191.
16. Siminovitich JM, Montie JE, Straffon RA. Prognostic indicators in renal adenocarcinoma. *J Urol*. 1983;130:20-23.
17. Skinner DG, Colvin RB, Vermillion DC, Pfester RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. *Cancer*. 1971;28:1165-1177.
18. Syrjänen K, Hjelt L. Grading of human renal adenocarcinoma. *Scand J Urol Nephrol*. 1978;12:49-55.
19. Greene FL, Page DL, Fleming ID, et al, eds. *AJCC Cancer Staging Manual*. 6th ed. New York: Springer; 2002.
20. Sobin LH, Wittekind C. *UICC TNM Classification of Malignant Tumours*. 6<sup>th</sup> ed. New York: Wiley-Liss; 2002.